Minutes 935th Meeting of the Minnesota Board of Pharmacy
335 Randolph Avenue, First Floor Board Room
St. Paul., MN 55102

Wednesday, August 19, 2026

Mission Statement
The Minnesota Board of Pharmacy exists to promote, preserve, and protect the public health, safety, and welfare by fostering the safe distribution of pharmaceuticals and the provision of quality pharmaceutical care to the citizens of Minnesota.

President Ronda Marie Chakolis-Hassan called the meeting to order at 10:06 am. This meeting was held in person and virtually. A roll call of Board members was taken, and a quorum declared.

Board members present:
- Ronda Marie Chakolis-Hassan
- Michael Haag
- Amy Paradis
- Ben Maisenbach
- Brandon Ordway
- Jake Manahan
- Barbara Dröher Klein
- Kendra Metz

Board members absent:
- Jana Rasmussen

Other Staff Present:
- Aaron Patterson, ED
- Katrina Howard, DD
- Tawnie Langenfeld
- Robert Johnson
- Ame Carlson
- Lisa Tollefson
- Kelly Hadsall
- Michele Mattila
- Krystal Sievert
- Brock Reed
- Julie Scott

1. Review and Approve Prior Meeting Minutes

Motion to approve: Michael Haag
Second: Brandon Ordway
Approved with unanimous consent.

2. Review and Approve Today's Agenda
   Executive Director Patterson noted a few adjustments to the agenda:
   - Tech advisory portion within policy discussion
   - Tele/remote portion within Dir Update
   - ED/DD will be a combined delivery
   - Pre-empt Policy discussion with Director updates

   Motion to approve with the above changes: Jake Manahan
   Second: Michael Haag
   Approved with unanimous consent.

3. President's Announcements and Updates
   President Chakolis-Hassan did not have any updates for the Board at this time.

4. Variances and Policy Review Committee
   - Consideration of the VPRC Report.
     Pharmacist board members will abstain from discussing or voting on issues involving potential conflict of interest, or their employers.

   Committee Chair Ame Carlson was available for questions or comments on report as submitted.
   Items are pulled for separate Board consideration as described below.

Motion to approve the consensus portion as submitted: Jake Manahan
Second: Michael Haag

- Ronda Marie Chakolis-Hassan – approve with abstention.
- Michael Haag – approve with abstention.
- Amy Paradis – approve with abstention.
- Ben Maisenbach – approve with abstention.
- Brandon Ordway – approve with abstention.
- Jake Manahan –approve.
- Kendra Metz – approve with abstention.
- Barbara Dröher Klein – approve.

Items deferred to Board due to Board member abstentions for: Fairview, Essentia, CVS, Methodist Hospital, Sterling, Omnicare. All recommended for approval by the VPRC. No discussion heard.

Motion to approve the consensus portion: Jake Manahan
Second: Michael Haag

- Ronda Marie Chakolis-Hassan – approve with abstention.
- Michael Haag – approve with abstention.
- Amy Paradis – approve with abstention.
- Ben Maisenbach – approve with abstention.
- Brandon Ordway – approve with abstention.
- Jake Manahan –approve.
- Kendra Metz – approve with abstention.
- Barbara Dröher Klein – approve.

5. Controlled Substances Reporting Section

   Report and upcoming publishing presented by Brock Reed. PMP education videos will be available soon. Dr. Reed described the department's recent WI Controlled Substance Board speaking engagement to encourage integrated interstate searching. There has been no response at this time, awaiting feedback.

Opiate Product Registration Fee program is seeking Board support to request an increase in appropriation. Per statute, this has not increased since its inception and they are seeking an increase of approximately 25%.
Board discussion was heard.

Motion to approve seeking the increase as stated: Jake Manahan
Second: Michael Haag

- Ronda Marie Chakolis-Hassan – approve.
- Michael Haag – approve.
- Amy Paradis – approve.
- Ben Maisenbach – approve.
- Brandon Ordway – approve.
- Jake Manahan – approve.
- Kendra Metz – approve.
- Barbara Dröher Klein – approve.

6. NABP District 5 meeting recap
   President Chakolis-Hassan shared the thank you note to attendees sent by event organizer Lloyd Jessen. Executive Director Patterson was recognized for the effort and organization to make the event successful.
   - Board members discussed highlights of the event and discussed takeaways and how to implement ideas brought forth through the presentations and discussions.
   - NABP Appointments
     - Deputy Director Katrina Howard was appointed to the Virtual Drug Manufacturer and Wholesaler Distributor Facilities Taskforce
     - Brandon Ordway was appointed as a Resolutions Committee alternate.
     - Deputy Director Howard reported that the District voted to advance two resolutions to the national committee for consideration:
       - 1. Central Repository for State License Verification and Authenticity Resources
       - 2. Advancing Interprofessional Regulatory Collaboration and Education Regarding Pharmacist Scope of Practice
     - District 5 will have the opportunity to have a representative on the Executive Committee in 2027.

7. Director Updates
   - Expedited Rulemaking: Deputy Director Howard
     - The Administrative Law Judge approved the Board's expedited rule. The rule was described and next steps outlined. The rule will become effective upon publication in the State Register.
   - July stats report awareness: Deputy Director Howard
     - Yearly stats are published on the Board's website.
   - Biennial cycle update: Deputy Director Howard
     - July 1, 2027, will begin the new biennium. Cyclical reports are required re

budget, profile, revenue, and expenditure projections. Informational only.

- Agency Profile: Executive Director Patterson
    - A document was presented, prepared as part of the biennium reporting. Director Patterson reviewed notable findings in increased licensing numbers, inspection count, and complaints. Discussion was heard.
- FY 2026 broad overview: Executive Director Patterson
    - The Board has hired a new surveyor, Krystal Sievert, present at the meeting.
    - As of July 2026, there are students already enrolled in the early MPJE program that was recently adopted.
    - The Board is engaged in cross agency work with the FDA, DEA, and MN Department of Agriculture as well as MN Department of Health regarding vaccination needs.
    - Additional financial information will be brought to the October meeting.
- Tele/Remote Advisory Taskforce: Executive Director Patterson
    - The taskforce is working toward final findings and report. Meeting minutes are posted on the Board's website. Discussion was heard surrounding the Board's existing guidance and the potential for recommendations for change by the taskforce to the board.
- Medications for Opioid Use Disorder update: Executive Director Patterson
    - A document entitled Pharmacist Prescriptive Authority for MOUD in Minnesota document is posted on the Board's website, as well as 2026 legislative changes affecting licensees and registrants. Considerations are underway regarding pharmacists' eligibility for DEA registration as a mid-level practitioner as well as payment for this service.
- Adopt Flavoring Guidance: Executive Director Patterson
    - A draft of flavoring guidance was presented for the Board's review. This change was enacted through the legislature and has caused a conflict between statute and Board rule. Guidance to licensees and registrants will provide clarity. Discussion was heard including a suggestion to include a carveout for medications with a narrow therapeutic index.

Motion to accept the guidance with above change without additional review: Michael Haag
Second: Brandon

- Ronda Marie Chakolis-Hassan – approve.
- Michael Haag – approve.
- Amy Paradis – approve.
- Ben Maisenbach – approve.
- Brandon Ordway – approve.
- Jake Manahan – approve.
- Kendra Metz – approve.
- Barbara Dröher Klein – approve.

- FY 2027 Initiatives:
    - Every 2 years a biennial report from all Health Licensing Board departments is published publicly.
    - Public Safety and Recent Board Actions/trends
        - Mass drug compounding: large organization compounding processes are being looked at by the Board and the FDA.
        - Med spas: Drugs or compounded drugs provided and dispensed outside of traditional practitioner spaces. The Board is working with other health licensing boards regarding practitioner education and guidance in those spaces, as our authority stops with the drugs themselves. Discussion heard.
- Legislative Updates and Priorities
    - Immunization in practice act
        - This did not go through during the last legislative session. The Board is seeking support to bring it back for the next session.
    - Technician Ratio
        - A bill was introduced by a state association last session which eliminated technician ratios and the Board's ability to modify ratios. The concept was opposed by the Board at its April meeting. The Director is seeking further Board member discussion regarding technician ratios in preparation for the session.
    - Standardization bill
        - Core updates for clarity and consistency regarding licensing and the application of late fees. The Board plans to reintroduce this bill with additional changes.
    - 151.065 Fee Amounts

    Elements were previously discussed and approved by the Board in Dec 2024.
        1. Reduction in reinstatement fees for individuals.
        2. Lower application and renewal fees for two subtypes of wholesalers, resident central repository and reverse distributors.
        3. Mailing list fees and the distinction between these proposed changes and the Board's no-cost, publicly accessible license verification tool.
        4. Creating a separate licensing fee for sterile compounding pharmacies. Discussion was heard from Board members and surveyor staff around the additional work required in inspection and review of these pharmacies.

Motion to support the Board staff recommendation of an increase in fees to $1000 for compounding pharmacies, with other pharmacy types to remain at $450: Jake Manahan
Second: Brandon Ordway

- Ronda Marie Chakolis-Hassan – approve.
- Michael Haag – approve.
- Amy Paradis – approve.
- Ben Maisenbach – approve.
- Brandon Ordway – approve.
- Jake Manahan – approve.

- Kendra Metz – approve.
- Barbara Dröher Klein – approve.

- Legislative Updates and Priorities (Continued)
    - Technical fix to 151.252 to correct an error referencing the fees statute.
    - 152.02 Controlled substances
        - Change strategy for the statute to adopt controlled substances act and federal scheduling, but create exceptions for the state where it differs from federal. The Board signaled agreement.
    - Kratom
        - The DEA temporarily classified kratom as schedule 1. This doesn't target kratom itself but kratom with certain levels of active components. MN Law has no exception or alternative scheduling. No action is required but the Board expressed support on the acceptance of current DEA scheduling.
    - 151.02
        - Amend this statute to add a pharmacy technician seat to the Board.

Motion to approve: Jake Manahan
Second: Michael Haag

- Ronda Marie Chakolis-Hassan – approve.
- Michael Haag – approve.
- Amy Paradis – approve.
- Ben Maisenbach – approve.
- Brandon Ordway – approve.
- Jake Manahan – approve.
- Kendra Metz – approve.
- Barbara Dröher Klein – approve.

8. Board Policy Discussions

Potential rules changes are being identified and triaged. This is a long process and will be an ongoing issue for the Board. Rules in Chapter 6800 brought to the Board for discussion/review:

- 700: this is outdated. Board discussion was heard on how best to update requirements.
- 1050: Simplify and require references and equipment applicable to practice. Remove requirement for hard copy references and list of specific references. Include statement of need for references applicable to practice setting. General agreement from the Board with minimal discussion.
- 1500: Clarity on prorating CE for newly registered/licensed or reinstated individuals; eliminate CE prior to reinstatement for technicians to lessen barriers to return to Minnesota's workforce. General agreement from the Board with minimal discussion.
- 1600: Repeal as obsolete. General agreement from the Board with minimal

discussion.

- 3100: Address certification to eliminate or significantly reduce variances. Discussion heard, Board is supportive with language updates.
- 3110: Remove language regarding family profile record. General agreement from the Board with minimal discussion.
- 3120: Changes regarding C2 transfers according to federal law. Discussion heard, additional language considerations needed.
- 3300: Clear inclusion of USP 800 and USP reference update, when compounding with hazardous drug preparations. Eliminates 2013 effective date. General agreement from the Board with minimal discussion.
- 3400: Add "expiration date or beyond use date, as applicable" to the minimum labeling requirement. General agreement from the Board with minimal discussion.
- 3850: Adjust minimum age requirement to 16 and eliminate the high school or equivalent degree requirement. General agreement from the Board with minimal discussion.
- 3850: Striking old 2014 language, training is required for renewal, and addition of a Minnesota-approved exam as acceptable training. General agreement from the Board with minimal discussion.
- 3850: Technician ratios. Board discussed possible ratio options. Will revisit at future meetings for further discussion.
- 3950: Eliminate the production of a hard copy daily summary of controlled substance transactions in 6800.3950, supb. 2D. The rule otherwise requires electronic data processing equipment to maintain transactions. General agreement from the Board with minimal discussion.
- 4050: Drug identification. General agreement from the Board with minimal discussion.
- 4210-4250: Schedule I-V Controlled Substances. Board discussion regarding repealing schedules of controlled substances from Rules as obsolete rules. Future policy discussion and vetting of CS scheduling strategy needed regarding issuing a scheduling order in accordance with Minn. Stats. §152.02, sub. 12.
- 5300: Registration and Reporting. Repeal as obsolete. General agreement from the Board with minimal discussion.
- 5350: Preceptors. Align registration expiration to pharmacist expiration dates, clean up CE language. General agreement from the Board with minimal discussion.
- 5600: Advisory Committee. Repeal. General agreement from the Board with minimal discussion.
- 7510: Patient care. Reference hazardous drugs and USP chapters appropriately. General agreement from the Board with minimal discussion.
- 8005: Cytotoxic agents. Reference hazardous drugs and cite USP chapters appropriately. General agreement from the Board with minimal discussion.
- 8300: Minimum standards. Cite USP chapters, 823 and 825. General agreement from the Board with minimal discussion.

- 9700: Update the Board's mailing address. General agreement from the Board with minimal discussion.

9. Miscellaneous Reports
    - CE Report
    - Pharmacist Licensing Report

    These reports are for informational purposes only and no action is needed by the Board.

Motion to adjourn: Michael Haag

Second: Kendra Metz

Meeting adjourned at 2:00pm

Upcoming Meetings

8/19/2026	Board Meeting	All	All
8/19/2026	CRP Completion	Metz	Kline
9/7/2026	**HOLIDAY CLOSED**	X	X
9/18/2026	ADDED: CRP Completion	Paradis	Ordway
9/16/2026	COPS Hearing	Metz	Chakolis-Hassan
9/23/2026	Variance	Kline	Maisenbach
10/7/2026	Board Meeting	All	All
10/7/2026	CRP Completion	Haag	Rasmussen